Clinical Trial Search

Primary: Minutes Per Week of Moderate-to-Vigorous Physical Activity (MPVA Min/wk) Assessed at 12 Weeks — 217.7; 203.2 MVPA minutes per week

Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 — -0.82; -0.1 Percentage of glycosylated hemoglobin — p=<0.0001

Primary: Change in Lung Function (Forced Expiratory Volume in 1 Second (FEV1) — 15.2; 20.1 percentage of change in FEV1

Primary: Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 0.50 D — 94.78 Percentage of Eyes

Primary: Comparing All Morning Bowel Prep to Evening Bowel Prep for Patients Undergoing Afternoon Colonoscopies. (Using Ottawa Scale Scores, Range 0-14) Lower Score Indicates a…

Primary: Number of Days of Heroin Use — 6.0; 6.4; 6.5; 4.0 days

Primary: Proportion of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) — 44.5; 6.3 percentage of participants — p=<0.001

Primary: Overall Survival — 10.0; 7.4 months — p=0.0096

Primary: Time to Progression Free Survival (PFS) — 25.9; 29.7 months — p=0.0081

Primary: AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to Time 24 Hours of TAK-536 (Azilsartan) — 6350.3; 6871.7 ng*hr/mL

Primary: Post-Release Opioid Relapse — 6; 15 participants

Primary: Complete Response. — 47; 15 percentage of evaluable subjects

Primary: Percentage of Participants Maintaining Mean Hemoglobin Concentration Within Plus or Minus (+/-) 1 Gram Per Deciliter (g/dL) of Reference and Within the Target Range…

Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale

Primary: Percentage of Participants With Both Hemoglobin Values of the Evaluation Phase in the Range of 11-12 Grams Per Deciliter (g/dL) — 10.67 percentage of participants